• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

Research Brief on 2-Methoxy-4,6-dimethylpyridine-3-carboxylic Acid (CAS: 65515-37-9): Recent Advances and Applications

2-Methoxy-4,6-dimethylpyridine-3-carboxylic acid (CAS: 65515-37-9) is a pyridine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and medicinal chemistry. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive compounds, particularly in the development of novel anti-inflammatory and antimicrobial agents. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and potential therapeutic applications.

One of the most notable advancements in the study of 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid is its role as a building block in the synthesis of heterocyclic compounds. Researchers have successfully utilized this compound to develop new classes of inhibitors targeting enzymes such as cyclooxygenase-2 (COX-2) and bacterial dihydrofolate reductase (DHFR). These inhibitors have shown promising results in preclinical studies, demonstrating significant anti-inflammatory and antibacterial activities. The structural flexibility of 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid allows for modifications that enhance its binding affinity and selectivity, making it a valuable scaffold in drug design.

In addition to its applications in drug discovery, recent studies have explored the physicochemical properties of 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid, including its solubility, stability, and pharmacokinetic profile. These investigations are critical for optimizing its use in pharmaceutical formulations. For instance, researchers have developed novel prodrug derivatives of this compound to improve its bioavailability and reduce potential side effects. Such advancements underscore the importance of 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid in the development of next-generation therapeutics.

Furthermore, the compound has been investigated for its potential role in targeted drug delivery systems. By conjugating 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid with nanoparticles or liposomes, scientists have achieved enhanced drug delivery to specific tissues or cells, thereby improving therapeutic efficacy and minimizing off-target effects. These innovations highlight the compound's versatility and its potential to address unmet medical needs in areas such as oncology and infectious diseases.

In conclusion, 2-methoxy-4,6-dimethylpyridine-3-carboxylic acid (CAS: 65515-37-9) continues to be a focal point of research in the chemical biology and pharmaceutical fields. Its unique structural features and broad applicability make it a promising candidate for the development of new therapeutic agents. Ongoing studies are expected to further elucidate its mechanisms of action and expand its applications, paving the way for innovative treatments in various disease areas. Researchers and industry professionals are encouraged to stay abreast of the latest developments related to this compound, as it holds significant potential for advancing drug discovery and improving patient outcomes.

• 72918-10-6(2-methoxy-6-methylpyridine-3-carboxylic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)